• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

葡甲胺锑酸盐在健康和婴儿利什曼原虫(杜氏利什曼原虫)感染的BALB/c小鼠体内的生物分布。

Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice.

作者信息

Borborema Samanta Etel Treiger, Osso João Alberto, Andrade Heitor Franco de, Nascimento Nanci do

机构信息

Centro de Biotecnologia, Instituto de Pesquisas Energéticas e Nucleares, Comissão Nacional de Energia Nuclear, São Paulo, SP, Brasil.

出版信息

Mem Inst Oswaldo Cruz. 2013 Aug;108(5):623-30. doi: 10.1590/0074-0276108052013014.

DOI:10.1590/0074-0276108052013014
PMID:23903979
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3970594/
Abstract

Pentavalent antimonials such as meglumine antimoniate (MA) are the primary treatments for leishmaniasis, a complex disease caused by protozoan parasites of the genus Leishmania . Despite over 70 years of clinical use, their mechanisms of action, toxicity and pharmacokinetics have not been fully elucidated. Radiotracer studies performed on animals have the potential to play a major role in pharmaceutical development. The aims of this study were to prepare an antimony radiotracer by neutron irradiation of MA and to determine the biodistribution of MA in healthy and Leishmania (Leishmania) infantum chagasi-infected mice. MA (Glucantime®) was neutron irradiated inside the IEA-R1 nuclear reactor, producing two radioisotopes, ¹²²Sb and ¹²⁴Sb, with high radionuclidic purity and good specific activity. This irradiated compound presented anti-leishmanial activity similar to that of non-irradiated MA in both in vitro and in vivo evaluations. In the biodistribution studies, healthy mice showed higher uptake of antimony in the liver than infected mice and elimination occurred primarily through biliary excretion, with a small proportion of the drug excreted by the kidneys. The serum kinetic curve was bi-exponential, with two compartments: the central compartment and another compartment associated with drug excretion. Radiotracers, which can be easily produced by neutron irradiation, were demonstrated to be an interesting tool for answering several questions regarding antimonial pharmacokinetics and chemotherapy.

摘要

五价锑化合物,如葡甲胺锑酸盐(MA),是治疗利什曼病的主要药物,利什曼病是一种由利什曼原虫属的原生动物寄生虫引起的复杂疾病。尽管已临床使用70多年,但其作用机制、毒性和药代动力学尚未完全阐明。在动物身上进行的放射性示踪研究有可能在药物研发中发挥重要作用。本研究的目的是通过对MA进行中子辐照制备一种锑放射性示踪剂,并确定MA在健康小鼠和感染婴儿利什曼原虫(Leishmania infantum chagasi)的小鼠体内的生物分布。MA(葡糖胺锑)在IEA-R1核反应堆内进行中子辐照,产生两种放射性同位素¹²²Sb和¹²⁴Sb,具有高放射性核素纯度和良好的比活度。在体外和体内评估中,这种辐照后的化合物表现出与未辐照MA相似的抗利什曼活性。在生物分布研究中,健康小鼠肝脏中锑的摄取量高于感染小鼠,排泄主要通过胆汁进行,少量药物通过肾脏排泄。血清动力学曲线呈双指数型,有两个房室:中央房室和另一个与药物排泄相关的房室。经证明,通过中子辐照可轻松制备的放射性示踪剂是回答有关锑药代动力学和化疗的几个问题的有趣工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0363/3970594/53c0e31ba89e/0074-0276-mioc-108-05-623-gf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0363/3970594/3720d0d949b7/0074-0276-mioc-108-05-623-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0363/3970594/ea60eefb2cee/0074-0276-mioc-108-05-623-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0363/3970594/53c0e31ba89e/0074-0276-mioc-108-05-623-gf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0363/3970594/3720d0d949b7/0074-0276-mioc-108-05-623-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0363/3970594/ea60eefb2cee/0074-0276-mioc-108-05-623-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0363/3970594/53c0e31ba89e/0074-0276-mioc-108-05-623-gf03.jpg

相似文献

1
Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice.葡甲胺锑酸盐在健康和婴儿利什曼原虫(杜氏利什曼原虫)感染的BALB/c小鼠体内的生物分布。
Mem Inst Oswaldo Cruz. 2013 Aug;108(5):623-30. doi: 10.1590/0074-0276108052013014.
2
Antimony determination in tissues and serum of hamsters infected with Leishmania garnhami and treated with meglumine antimoniate.感染杜氏利什曼原虫并接受葡甲胺锑酸盐治疗的仓鼠组织和血清中的锑含量测定
Ann Trop Med Parasitol. 1994 Feb;88(1):37-41. doi: 10.1080/00034983.1994.11812832.
3
Meglumine Antimoniate (Glucantime) Causes Oxidative Stress-Derived DNA Damage in BALB/c Mice Infected by Leishmania (Leishmania) infantum.葡甲胺锑酸盐(葡糖胺锑,Glucantime)在感染婴儿利什曼原虫(利什曼原虫属)的BALB/c小鼠中导致氧化应激诱导的DNA损伤。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.02360-16. Print 2017 Jun.
4
Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum.多次给药后葡甲胺锑酸盐在实验感染婴儿利什曼原虫的犬体内的药代动力学。
Vet Parasitol. 1998 Feb 15;75(1):33-40. doi: 10.1016/s0304-4017(97)00193-3.
5
In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.婴儿利什曼原虫菌株对五价锑的体外敏感性在体外或体内传代过程中未发生改变,但在用葡甲胺锑酸盐治疗宿主后会发生改变。
BMC Pharmacol. 2002 May 2;2:11. doi: 10.1186/1471-2210-2-11.
6
Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in Leishmania infantum-Infected BALB/c Mice.常规和聚乙二醇化两性霉素 B 脂质体的混合配方可减少利什曼原虫感染 BALB/c 小鼠的炎症反应和寄生虫负担。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.00962-17. Print 2017 Nov.
7
Pharmacokinetics of neutron-irradiated meglumine antimoniate in -infected BALB/c mice.中子辐照葡甲胺锑酸盐在感染的BALB/c小鼠体内的药代动力学
J Venom Anim Toxins Incl Trop Dis. 2019 Mar 11;25:e144618. doi: 10.1590/1678-9199-JVATITD-1446-18. eCollection 2019.
8
Polycaprolactone Antimony Nanoparticles as Drug Delivery System for Leishmaniasis.聚己内酯锑纳米粒子作为利什曼病的药物传递系统。
Am J Ther. 2019 Jan/Feb;26(1):e12-e17. doi: 10.1097/MJT.0000000000000539.
9
Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance.葡甲胺锑酸盐细胞毒性及多药耐药相关蛋白1(MRP1)介导的耐药中残余Sb(III)的作用
Chem Biol Interact. 2006 Apr 15;160(3):217-24. doi: 10.1016/j.cbi.2006.01.008. Epub 2006 Mar 9.
10
Pharmacokinetic of meglumine antimoniate encapsulated in phosphatidylserine-liposomes in mice model: A candidate formulation for visceral leishmaniasis.磷脂酰丝氨酸脂质体包裹的葡甲胺锑的药代动力学:一种适合内脏利什曼病的候选制剂。
Biomed Pharmacother. 2018 Jul;103:1609-1616. doi: 10.1016/j.biopha.2018.05.004. Epub 2018 May 7.

引用本文的文献

1
Emetic Tartar-Loaded Liposomes as a New Strategy for Leishmaniasis Treatment.载吐酒石脂质体作为治疗利什曼病的新策略
Pharmaceutics. 2023 Mar 10;15(3):904. doi: 10.3390/pharmaceutics15030904.
2
Effectiveness of an -Alkyl Hydroxamate in Dogs with Naturally Acquired Canine Leishmaniosis: An Exploratory Clinical Trial.一种α-烷基异羟肟酸酯对自然感染犬利什曼病犬的有效性:一项探索性临床试验。
Animals (Basel). 2022 Oct 7;12(19):2700. doi: 10.3390/ani12192700.
3
Pre-clinical evaluation of LASSBio-1491: From in vitro pharmacokinetic study to in vivo leishmanicidal activity.

本文引用的文献

1
Leishmaniasis worldwide and global estimates of its incidence.全球利什曼病及其发病率的全球估计。
PLoS One. 2012;7(5):e35671. doi: 10.1371/journal.pone.0035671. Epub 2012 May 31.
2
Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.含葡甲胺锑的脂质体在感染利什曼原虫(利什曼原虫)的巨噬细胞中的摄取和抗利什曼原虫活性。
Int J Antimicrob Agents. 2011 Oct;38(4):341-7. doi: 10.1016/j.ijantimicag.2011.05.012. Epub 2011 Jul 23.
3
New delivery strategies for the old pentavalent antimonial drugs.
LASSBio-1491 的临床前评估:从体外药代动力学研究到体内抗利什曼原虫活性。
PLoS One. 2022 Jun 6;17(6):e0269447. doi: 10.1371/journal.pone.0269447. eCollection 2022.
4
Licochalcone a Exhibits Leishmanicidal Activity and in Experimental Model of () .甘草查尔酮A在()实验模型中表现出抗利什曼原虫活性。 (注:原文括号处内容缺失)
Front Vet Sci. 2020 Dec 10;7:527. doi: 10.3389/fvets.2020.00527. eCollection 2020.
5
Pharmacokinetics of neutron-irradiated meglumine antimoniate in -infected BALB/c mice.中子辐照葡甲胺锑酸盐在感染的BALB/c小鼠体内的药代动力学
J Venom Anim Toxins Incl Trop Dis. 2019 Mar 11;25:e144618. doi: 10.1590/1678-9199-JVATITD-1446-18. eCollection 2019.
6
Molecular Cloning and Biochemical Characterization of Iron Superoxide Dismutase from Leishmania braziliensis.来自巴西利什曼原虫的铁超氧化物歧化酶的分子克隆与生化特性分析
Mol Biotechnol. 2018 Aug;60(8):595-600. doi: 10.1007/s12033-018-0095-2.
7
Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis.单剂量脂质体两性霉素 B 在实验内脏利什曼病不同阶段的药效学和生物分布。
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00497-17. Print 2017 Sep.
8
Immucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral Leishmaniasis.免疫菌素ImmA和ImmH在实验性内脏利什曼病治疗中有效且无毒。
PLoS Negl Trop Dis. 2015 Dec 23;9(12):e0004297. doi: 10.1371/journal.pntd.0004297. eCollection 2015 Dec.
9
Tissue distribution of residual antimony in rats treated with multiple doses of meglumine antimoniate.多次给予葡甲胺锑酸盐治疗的大鼠体内残余锑的组织分布。
Mem Inst Oswaldo Cruz. 2014 Jul;109(4):420-7. doi: 10.1590/0074-0276140030.
新型五价锑老药投送策略。
Expert Opin Drug Deliv. 2010 Dec;7(12):1343-58. doi: 10.1517/17425247.2010.529897. Epub 2010 Oct 28.
4
The correlation between distribution of antimony in tissues and chemotherapeutic effect in experimental leishmaniasis.
J Pharmacol Exp Ther. 1946 Oct;88(2):162-72.
5
Control of neglected tropical diseases.被忽视热带病的防控
N Engl J Med. 2007 Sep 6;357(10):1018-27. doi: 10.1056/NEJMra064142.
6
Synthesis and antileishmanial activities of novel 3-substituted quinolines.新型3-取代喹啉的合成及其抗利什曼原虫活性
Antimicrob Agents Chemother. 2005 Mar;49(3):1076-80. doi: 10.1128/AAC.49.3.1076-1080.2005.
7
Leishmaniasis: drugs in the clinic, resistance and new developments.利什曼病:临床用药、耐药性及新进展
Drug Resist Updat. 2004 Aug-Oct;7(4-5):257-66. doi: 10.1016/j.drup.2004.07.002.
8
Leishmaniasis: current situation and new perspectives.利什曼病:现状与新展望。
Comp Immunol Microbiol Infect Dis. 2004 Sep;27(5):305-18. doi: 10.1016/j.cimid.2004.03.004.
9
Urinary excretion of antimony after administration of methyl glucamine antimoniate. preliminary observations.葡甲胺锑酸盐给药后锑的尿排泄。初步观察。
Ind Med Gaz. 1950 Sep;85(9):388-91.
10
Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.肠肝循环:生理、药代动力学及临床意义。
Clin Pharmacokinet. 2002;41(10):751-90. doi: 10.2165/00003088-200241100-00005.